<code id='AFDE85800D'></code><style id='AFDE85800D'></style>
    • <acronym id='AFDE85800D'></acronym>
      <center id='AFDE85800D'><center id='AFDE85800D'><tfoot id='AFDE85800D'></tfoot></center><abbr id='AFDE85800D'><dir id='AFDE85800D'><tfoot id='AFDE85800D'></tfoot><noframes id='AFDE85800D'>

    • <optgroup id='AFDE85800D'><strike id='AFDE85800D'><sup id='AFDE85800D'></sup></strike><code id='AFDE85800D'></code></optgroup>
        1. <b id='AFDE85800D'><label id='AFDE85800D'><select id='AFDE85800D'><dt id='AFDE85800D'><span id='AFDE85800D'></span></dt></select></label></b><u id='AFDE85800D'></u>
          <i id='AFDE85800D'><strike id='AFDE85800D'><tt id='AFDE85800D'><pre id='AFDE85800D'></pre></tt></strike></i>

          entertainment

          entertainment

          author:leisure time    Page View:2
          Nasdaq
          Mark Lennihan/AP

          Alkermes shareholders voted Thursday to re-elect all of the drugmaker’s current directors, ending an acrimonious proxy fight with hedge fund Sarissa Capital Management, which had sought to seat three directors on the board.

          At the company’s annual meeting, shareholders voted in favor of Alkermes’ proposal to retain all seven of the director nominees to the 11-person board.

          advertisement

          The outcome is a setback for Sarissa, which owns 8.5% of Alkermes and is run by activist investor Alex Denner. Sarissa has accused Alkermes executives of mismanaging the business and destroying shareholder value.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          Medicare details structure of new drug price negotiation program
          Medicare details structure of new drug price negotiation program

          MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

          read more
          Keeping primary care docs in field isn't impossible, says AAFP CEO
          Keeping primary care docs in field isn't impossible, says AAFP CEO

          R.ShawnMartin,theCEOoftheAmericanAcademyofFamilyPhysiciansCourtesyAmericanAcademyofFamilyPhysiciansI

          read more
          Cancer drug shortages should be causing more outrage
          Cancer drug shortages should be causing more outrage

          DrugshortagesareagrowingproblemintheU.S.,andashortageoflivesavingcancerdrugsinparticularhasreachedcr

          read more

          Anger, defiance, fear over Supreme Court decision to block student loan forgiveness

          PeopleinfavorofcancelingstudentdebtprotestoutsidetheSupremeCourt,June30,2023,asdecisionsareexpectedi